In an effort to increase patient access to innovative investigational medicines, Sanofi will partner with Inato to connect with community-based sites around the world.
Sanofi and Inato, a global platform that seamlessly connects community-based sites with pharmaceutical companies looking to prioritize access and diversity in clinical trials, are working together to expand the pharma company’s global Immunology footprint. This multi-year effort will leverage more than 350 community-based research sites to bring clinical trials to more people across the world.
The portfolio-wide project will focus on clinical trials across immunology, including COPD, asthma, ulcerative colitis, chronic spontaneous urticaria, and atopic dermatitis. Inato’s network of more than 2,500 community-based sites will allow Sanofi to reach previously untapped patient populations, improve diversity and inclusion, accelerate trial timelines, and hit enrollment targets.
Sanofi is also striving to increase diversity across its trials with Inato’s Inclusive Research Program. This initiative allows the company to connect with proven-diverse sites that have access to representative patient populations needed for each trial.
“Community-based sites hold the key to unlocking access for patients across the world,” said Kourosh Davarpanah, Co-founder & CEO of Inato. “The doctors and site staff that we work with commonly live in the areas they serve. This makes them better able to build trust with patients and establish the necessary support to enroll and retain diverse trial participants. We are thrilled to bring Sanofi’s innovative immunology portfolio to these communities and improve access for previously underserved populations.”
To date, Sanofi and Inato have launched 9 studies together. Across the 7 studies that have begun site selection, Sanofi has selected 63 community-based sites in 9 countries. These sites represent a potential enrollment of 290 patients across the trials through Inato’s Verified Commitment (IVC).
In a Phase II Multiple Sclerosis trial, the total IVC was met, meaning all Inato sites reached their enrollment targets. One of these community sites in Charlotte, North Carolina achieved the First-Patient-In in the United States and went on to be a high-enroller, enrolling 3 patients compared to the target of 1 patient per site.